Why Biohaven Stock Crushed it on Monday
Biohaven (NYSE: BHVN) stock got quite the shot in the arm as the trading week began. On Monday, an analyst initiated coverage of the clinical-stage biotech with a very bullish buy recommendation; not suprisingly, investors took this to heart and pushed the price of the shares up by more than 10% that trading session.
The person behind the initiation was Canaccord Genuity's Sumant Kulkami, who flagged Biohaven as a buy with a price target of $21 per share. That figure is significant, as it's more than double Biohaven's present level, even after the Monday price pop.
Image source: Getty Images.
Source Fool.com
Canaccord Financial Inc. Aktie
?
-0,67 %
